Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Diabetic Gastroparesis Treatment Market – Insights

Diabetic gastroparesis is delayed gastric emptying associated with diabetes. The condition occurs in patients suffering from both type-1 and type- 2 diabetes and is more common in female patients suffering from type-2 diabetes. The disease involves delayed emptying of the stomach leading to a series of symptoms such as nausea, vomiting, abdominal bloating, abdominal pain, weight loss, gastroesophageal reflux, spasms of the stomach wall, and heartburn.

The global diabetic gastroparesis treatment market is estimated to account for US$ 3,069.8 Mn in terms of value in 2018 and is expected to reach US$ 4,252.2 Mn by the end of 2027.

Global Diabetic Gastroparesis Treatment Market: Drivers

Increasing prevalence of diabetes is expected to propel growth of the global diabetic gastroparesis treatment market over the forecast period. For instance, according to the study, ‘Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028)’, published by the American Diabetes Association, 500 million people worldwide suffered from type 2 diabetes in 2018.

Moreover, easy access to off-label medicines without prescriptions is expected to boost growth of the market. Medications such as anti-emetic drugs (oandesteron) are affordable and easily accessible in emerging economies. Moreover, increasing inclination towards OTC medicines to avoid higher expenses is also leading to greater disbursement of drugs through retail pharmacies and drugstores.

North America region held dominant position in the global diabetic gastroparesis treatment market in 2018, accounting for 38.5% share in terms of value, followed by Europe.

Diabetic Gastroparesis Treatment  | Coherent Market Insights

Global Diabetic Gastroparesis Treatment Market: Restraints

Lack of clinical evidence on improvement offered by prescription drugs is expected to hinder growth of the global diabetic gastroparesis treatment market. There is very little documented clinical evidence provided for prescription drugs for the treatment of diabetic gastroparesis. Metoclopramide, domperidon, and erythromycin are used for the treatment of diabetic gastroparesis. However, approvals of these drugs are inconsistent across countries, leading to lack of availability of consistent patient improvement data due to administration of these drugs. In emerging economies, the disease remains largely untreated or often treated through non-prescription OTC drugs, which again is responsible for dearth of clinical evidence regarding improvement in quality of life for patients after consuming these drugs for the treatment of diabetic gastroparesis.

Moreover, withdrawal/termination of clinical trials is also expected to hamper growth of the market. There are very few drugs in the pipeline, which have the potential for the treatment of diabetic gastroparesis. This is due to early termination of clinical trials or failure of drugs to meet statistically significant endpoints. For instance, in August 2018, Dartmouth-Hitchcock Medical Center terminated the randomized, double-blind, placebo-controlled trial of promethazine for treatment of diabetic gastroparesis, conducted in collaboration with American College of Gastroenterology, due to lack of recruitment.

Global Diabetic Gastroparesis Treatment Market: Opportunities 

Measures to support product approval and labeling claims for diabetic gastroparesis treatments is expected to offer lucrative growth opportunities for players in the global diabetic gastroparesis treatment market. For instance, in February 2019, a team of researchers affiliated with Boston Therapeutics, Inc. reported that The Diabetic Gastroparesis Symptom Severity Diary can be a reliable and valid measure that can be used to derive endpoints to evaluate treatment benefit in future diabetic gastroparesis interventional trials.

Moreover, initiatives of regulatory bodies to issue guidance for development of drugs for the treatment of diabetic gastroparesis is also expected to aid in growth of the market. For instance, in August 2019, the U.S. FDA issued guidance that addresses FDA’s current recommendations regarding clinical trial designs and clinical endpoint assessments to support the development of drugs for the treatment of idiopathic and diabetic gastroparesis.

Diabetic Gastroparesis Treatment  | Coherent Market Insights

Drugs segment in the global diabetic gastroparesis treatment market was valued at US$ 1,924.5 Mn in 2018 and is expected to reach US$ 2,646.8 Mn by 2027 at a CAGR of 3.6% during the forecast period.

Market Trends/Key Takeaways

The market is witnessing R&D in non-invasive approaches for the treatment of diabetic gastroparesis. For instance, a pilot study presented at the 2019 annual meeting of the North American Neuromodulation Society assessed the effectiveness of the gammaCore hand-held vagal nerve stimulator for the treatment of gastroparesis.

Gastric Per-Oral Endoscopic Pyloromyotomy (GPOEM) is a safe and effective therapy for refractory gastroparesis. For instance, researchers from Emory University (U.S) assessed the safety and efficacy of GPOEM and compared clinical outcomes between diabetic and non-diabetic cohorts and found that patients with predominant nausea/vomiting and short duration of diabetic gastroparesis may opt for GPOEM.

Regulations

U.S.

ICD-10-CM

  • Reimbursement claims with a date of service on or after Oct 1, 2015 require the use of ICD-10-CM codes
  • This is the American ICD-10-CM version of K31.84. Other international ICD-10 versions may differ
  • 61 (diabetes with neurological manifestations)
  • 3 (gastroparesis)
  • 43 (Type 1 diabetes mellitus with diabetic autonomic [poly]neuropathy)

ICD-9-CM

  • Diabetes type 1 with gastroparesis
  • Diabetes type 2 with gastroparesis
  • Diabetic gastroparesis
  • Diabetic gastroparesis associated with type 1 diabetes mellitus
  • diabetic gastroparesis associated with type 2 diabetes mellitus
  • DM 1 w diabetic gastroparesis
  • DM 2 W diabetic gastroparesis
  • Gastroparesis due to diabetes
  • Gastroparesis due to DM
  • Gastroparesis syndrome
  • 3 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim
  • gastrica 536.8
  • neurogenic 536.3
  • psychogenic 306.4
  • dyspepsia 536.3
  • psychogenic 306.4
  • stomach 536.3
  • neurotic or psychogenic 306.4
  • psychogenic 306.4
  • Diabetic gastroparesis drugs are eligible for reimbursement in in-patient hospitalization cases, when there a proven medical necessity
  • Diabetic gastroparesis treatment devices are medically necessary as these are used in severe cases of refractory gastroparesis. These are eligible for reimbursement from both public and private payers in the U.S.

Diabetic Gastroparesis Treatment  | Coherent Market Insights

Global Diabetic Gastroparesis Treatment Market: Key Developments 

Major players operating in the global diabetic gastroparesis treatment market include, Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc. (Becton, Dickinson and Company), Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc.

Global Diabetic Gastroparesis Treatment Market: Key Developments 

Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in January 2020, Evoke Pharma, Inc., a developer of drugs for the treatment of gastrointestinal disorders and diseases, announced that the U.S. FDA accepted the company’s resubmission of its 505(b)(2) New Drug Application (NDA) for Gimoti, a nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis.

Major players in the market are also focused on conducting clinical trials to expand their product portfolio. For instance, in December 2018, Vanda Pharmaceuticals, Inc. announced that tradipitant met the primary endpoint in a Phase II clinical study in patients with idiopathic and diabetic gastroparesis.

Diabetic gastroparesis involves digestive system issue associated with diabetes. Chronic Diabetes hampers functioning of various organs, and nervous system including vagus nerve. Vagus nerve controls stomach emptying activity or the time duration for stomach emptying i.e. how quick or slow. Damaged vagus serve affects digestion, and food stays for longer time in the body than required. This condition is called as gastroparesis, and is more common in people with type 1 diabetes, though type 2 diabetes patients can also get it. Research and development of newer treatment options such as nasal sprays is expected to support growth of the market over the forecast period. For instance, on 27 January 2020, Evoke Pharma, Inc., received Notice of Allowance for the Gimoti trademark from United States Patent and Trademark Office (USPTO). Gimoti is a nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis. It is currently under review process for New Drug Disease Indication (NDA) by U.S. FDA and has a target Prescription Drug User Fee Act (PDUFA) of June 19, 2020.

Restraints of the Global Diabetic Gastroparesis Treatment Market

Factors such as lack of clinical evidence on improvement offered by prescription drugs, withdrawal/termination of clinical trials is also expected to hamper growth of the market.

Key features of the study:

  • This report provides in-depth analysis of the global diabetic gastroparesis treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global diabetic gastroparesis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc. (Becton, Dickinson and Company), Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global diabetic gastroparesis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Diabetic Gastroparesis Treatment Market, By Product Type:
    • Drugs
      • Gastroprokinetic Agents
      • Antiemetic Agents
      • Botulinum Toxin
    • Surgical Treatment Products
      • Gastric Electrical Stimulation (GES) Device
      • Percutaneous Endoscopic Gastrostomy (PEG) Kit
      • Parenteral Nutrition
  • Global Diabetic Gastroparesis Treatment Market, By Disease Indication:
    • Compensated Gastroparesis
    • Gastric Failure
  • Global Diabetic Gastroparesis Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Diabetic Gastroparesis Treatment Market, By Geography:
    • North America
      • By Product Type
        • Drugs
          • Gastroprokinetic Agents
          • Antiemetic Agents
          • Botulinum Toxin
        • Surgical Treatment Products
          • Gastric Electrical Stimulation (GES) Device
          • Percutaneous Endoscopic Gastrostomy (PEG) Kit
          • Parenteral Nutrition
      • By Disease Indication
        • Compensated Gastroparesis
        • Gastric Failure
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Product Type
        • Drugs
          • Gastroprokinetic Agents
          • Antiemetic Agents
          • Botulinum Toxin
        • Surgical Treatment Products
          • Gastric Electrical Stimulation (GES) Device
          • Percutaneous Endoscopic Gastrostomy (PEG) Kit
          • Parenteral Nutrition
      • By Disease Indication
        • Compensated Gastroparesis
        • Gastric Failure
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type
        • Drugs
          • Gastroprokinetic Agents
          • Antiemetic Agents
          • Botulinum Toxin
        • Surgical Treatment Products
          • Gastric Electrical Stimulation (GES) Device
          • Percutaneous Endoscopic Gastrostomy (PEG) Kit
          • Parenteral Nutrition
      • By Disease Indication
        • Compensated Gastroparesis
        • Gastric Failure
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Product Type
        • Drugs
          • Gastroprokinetic Agents
          • Antiemetic Agents
          • Botulinum Toxin
        • Surgical Treatment Products
          • Gastric Electrical Stimulation (GES) Device
          • Percutaneous Endoscopic Gastrostomy (PEG) Kit
          • Parenteral Nutrition
      • By Disease Indication
        • Compensated Gastroparesis
        • Gastric Failure
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Product Type
        • Drugs
          • Gastroprokinetic Agents
          • Antiemetic Agents
          • Botulinum Toxin
        • Surgical Treatment Products
          • Gastric Electrical Stimulation (GES) Device
          • Percutaneous Endoscopic Gastrostomy (PEG) Kit
          • Parenteral Nutrition
      • By Disease Indication
        • Compensated Gastroparesis
        • Gastric Failure
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type
        • Drugs
          • Gastroprokinetic Agents
          • Antiemetic Agents
          • Botulinum Toxin
        • Surgical Treatment Products
          • Gastric Electrical Stimulation (GES) Device
          • Percutaneous Endoscopic Gastrostomy (PEG) Kit
          • Parenteral Nutrition
      • By Disease Indication
        • Compensated Gastroparesis
        • Gastric Failure
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Janssen Global Services, LLC *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Cardinal Health, Inc.
    • Evoke Pharma, Inc.
    • Salix Pharmaceuticals, Inc.
    • Alfa Wassermann SPA
    • Abbott Laboratories
    • Medtronic Plc.
    • C. R. Bard, Inc. (Becton, Dickinson and Company)
    • Rhythm Pharmaceuticals, Inc.
    • Boston Scientific Corporation
    • Kimberly-Clark Corporation
    • Vanda Pharmaceuticals, Inc.
    • Allergan, plc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Disease Indication
      • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
  4. Global Diabetic Gastroparesis Treatment Market, By Product Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • Gastroprokinetic Agents
        • Antiemetic Agents
        • Botulinum Toxin
    • Surgical Treatment Products
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • Gastric Electrical Stimulation (GES) Device
        • Percutaneous Endoscopic Gastrostomy (PEG) Kit
        • Parenteral Nutrition
  5. Global Diabetic Gastroparesis Treatment Market, By Disease Indication, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Compensated Gastroparesis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Gastric Failure
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Diabetic Gastroparesis Treatment Market, By Distribution Channel, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Diabetic Gastroparesis Treatment Market, By Regions, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • Janssen Global Services, LLC
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Cardinal Health, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Evoke Pharma, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Salix Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Alfa Wassermann SPA
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Medtronic Plc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • C. R. Bard, Inc. (Becton, Dickinson and Company)
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Rhythm Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Boston Scientific Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Kimberly-Clark Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Vanda Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Allergan, plc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 34 market data tables and 25 figures on “Diabetic Gastroparesis Treatment Market – Global forecast to 2027.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner